PCM
GOSS icon

Prelude Capital Management’s Gossamer Bio GOSS Stock Holding History

Prelude Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-136,200
Closed -$422K – 1360
2025
Q4 		$422K Hold
136,200
– – 0.03% 611
2025
Q3 		$358K Sell
136,200
-237,969
-64% -$525K 0.03% 636
2025
Q2 		$460K Sell
374,169
-2,633
-0.7% -$2.87K 0.04% 467
2025
Q1 		$414K Sell
376,802
-38,045
-9% -$44K 0.03% 572
2024
Q4 		$375K Buy
414,847
+310,235
+297% +$266K 0.02% 702
2024
Q3 		$103K Buy
+104,612
New +$101K 0.01% 1150

Other funds holding GOSS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Prelude Capital Management's GOSS Position: Q1 2026 in Review

Prelude Capital Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 136,200 shares — an estimated $422K sold.

Prelude Capital Management first reported a position in GOSS in Q3 2024 and held it in 6 quarters. The position peaked at $460K in Q2 2025. 185 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Prelude Capital Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 136,200 Gossamer Bio shares in Q1 2026, an estimated $422K.
  • Prelude Capital Management first reported a position in Gossamer Bio in Q3 2024 and held it in 6 quarters.
  • Prelude Capital Management's Gossamer Bio position peaked at $460K in Q2 2025.
  • 185 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.